Despite considerable progress, ocular gene therapy development remains challenging – but an emphasis on more efficient preclinical processes could streamline the route to market for valuable therapies
1
min read
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.